☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
SELLAS
SELLAS Reports Results for SLS009 in P-IIa Trial for the Treatment of Acute Myeloid Leukemia (AML)
March 27, 2024
PharmaShots Weekly Snapshots (October 09–13, 2023) _
October 14, 2023
SELLAS Receives the US FDA’s Orphan Drug Designation to SLS009 for the Treatment of Acute Myeloid Leukemia
October 12, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.